A61K 9/08
Solutions
Official title: Solutions {(composition of solutions A61K47/00)}
A61K9/08 (Solutions) appears on 5,395 US grants and 10,684 published applications in this corpus.
Search patents in A61K- Granted patents
- 5,395
- Published applications
- 10,684
- Assignees
- 3,863
- Inventors
- 15,675
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 3 | 0 |
| 1979 | 2 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 3 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 5 | 0 |
| 1996 | 3 | 0 |
| 1997 | 10 | 0 |
| 1998 | 16 | 0 |
| 1999 | 26 | 0 |
| 2000 | 10 | 0 |
| 2001 | 19 | 8 |
| 2002 | 27 | 43 |
| 2003 | 21 | 48 |
| 2004 | 15 | 61 |
| 2005 | 10 | 48 |
| 2006 | 22 | 82 |
| 2007 | 22 | 95 |
| 2008 | 20 | 119 |
| 2009 | 15 | 121 |
| 2010 | 41 | 234 |
| 2011 | 54 | 163 |
| 2012 | 81 | 257 |
| 2013 | 124 | 300 |
| 2014 | 158 | 339 |
| 2015 | 231 | 391 |
| 2016 | 271 | 633 |
| 2017 | 317 | 695 |
| 2018 | 375 | 673 |
| 2019 | 394 | 771 |
| 2020 | 485 | 846 |
| 2021 | 497 | 954 |
| 2022 | 452 | 865 |
| 2023 | 411 | 838 |
| 2024 | 464 | 771 |
| 2025 | 480 | 747 |
| 2026 | 296 | 582 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Ketamine formulation6 Oct 2026US 12,751,918 B2Fresenius Kabi USA, LLC
- Stable levothyroxine compositions in aprotic polar solvents6 Oct 2026US 12,751,937 B2Xeris Pharmaceuticals, Inc.
- Injectable formulations in a method for treating pain6 Oct 2026US 12,751,943 B2Pelthos Therapeutics Inc.
- Oral liquid formulation of apixaban6 Oct 2026US 12,751,947 B2Liqmeds Worldwide Limited
- Method for treating tumours by capturing copper and/or iron6 Oct 2026US 12,752,018 B2Centre National De La Recherche Scentifique (Cnrs)
- Formulation for an effective oral administration of ciclopirox with no adversal gastrointestinal toxicity8 Oct 2026US 2026/0306400 A1AsociacióN Centro De InvestigacióN Cooperativa En Biociencias-Cic Biogune
- Water-based liquid preparation8 Oct 2026US 2026/0306443 A1Senju USA, Inc.
- Sulfurized imidazoles in ophthalmic formulations8 Oct 2026US 2026/0306457 A1Geneiii Biotech Company Ltd.
- Amlodipine formulations8 Oct 2026US 2026/0306467 A1Azurity Pharmaceuticals, Inc.
- Polymorphic forms and formulations of leriglitazone8 Oct 2026US 2026/0306468 A1Minoryx Therapeutics S.L.
Most cited
By later US patents
- Method of reducing TNF.alpha. levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines288US 5,635,517 ACelgene Corporation · 1997
- Frozen piercing implements and methods for piercing a substrate284US 8,784,385 B2The Invention Science Fund I, LLC · 2014
- Protein formulation234US 6,685,940 B2Genentech, Inc. · 2004
- Personal safety mobile notification system229US 8,624,727 B2Saigh and Son, LLC · 2014
- Methods and compositions for improving digestion and absorption in the small intestine216US 5,977,175 ACedars-Sinai Medical Center · 1999